Holen Sie sich die Stockscreener-App
4.94
0.00%
0.00
Handel nachbörslich:
4.95
0.010
+0.20%
Schlusskurs vom Vortag:
$4.94
Offen:
$4.97
24-Stunden-Volumen:
4.18M
Relative Volume:
0.71
Marktkapitalisierung:
$1.35B
Einnahmen:
$8.10M
Nettoeinkommen (Verlust:
$-92.72M
KGV:
-13.83
EPS:
-0.3571
Netto-Cashflow:
$-82.52M
1W Leistung:
-2.76%
1M Leistung:
+69.18%
6M Leistung:
+171.43%
1J Leistung:
+150.76%
1-Tages-Spanne:
$4.91
$5.20
1-Wochen-Bereich:
$4.43
$5.33
52-Wochen-Spanne:
$1.05
$5.5082
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Vergleichen Sie TSHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.94 | 1.40B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.63 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.00 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.69 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.18 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.03 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Eingeleitet | BofA Securities | Buy |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Why Taysha Gene Therapies Inc. stock is rated strong buyOil Prices & Community Verified Trade Signals - newser.com
Why Taysha Gene Therapies Inc. stock is favored by top institutionsPortfolio Growth Summary & Real-Time Sentiment Analysis - newser.com
How institutional ownership impacts Taysha Gene Therapies Inc. stock2025 Biggest Moves & Weekly Watchlist for Hot Stocks - newser.com
Taysha regains full rights to TSHA-102 gene therapy for Rett - Rett Syndrome News
Chart overlay techniques for tracking Taysha Gene Therapies Inc.Earnings Performance Report & AI Driven Stock Movement Reports - newser.com
Candlestick signals on Taysha Gene Therapies Inc. stock todayCPI Data & Advanced Technical Analysis Signals - newser.com
Tick level data insight on Taysha Gene Therapies Inc. volatilityQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com
Raymond James Initiates Coverage on TSHA with Strong Buy Rating - GuruFocus
Taysha soars on FDA breakthrough therapy status for lead asset - MSN
Published on: 2025-10-21 00:17:01 - newser.com
Why Taysha Gene Therapies Inc. is moving today2025 Macro Impact & Free Accurate Trade Setup Notifications - newser.com
Will Taysha Gene Therapies Inc. stock continue dividend increasesEarnings Summary Report & Free AI Powered Buy and Sell Recommendations - newser.com
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Using R and stats models for Taysha Gene Therapies Inc. forecastingJuly 2025 Levels & Risk Managed Investment Signals - newser.com
What analysts say about Taysha Gene Therapies Inc stockStock Correlation Metrics & Zero-Cost Stock Research by Professionals - earlytimes.in
Taysha Gene Therapies Eyes Volatility Amid Key Developments - StocksToTrade
Taysha Gene Therapies Faces Challenging Market Following Recent Developments - timothysykes.com
Retail Trends: Can Taysha Gene Therapies Inc. stock double in next 5 yearsJuly 2025 WrapUp & Weekly Stock Breakout Alerts - nchmf.gov.vn
Will Taysha Gene Therapies Inc. stock maintain growth story2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com
Taysha Gene Therapies Faces Financial Pressure: Concerns Amid Heavy Losses - StocksToTrade
Taysha Gene Therapies Faces New Challenges Amid Market Volatility - timothysykes.com
Aug Summary: Will Taysha Gene Therapies Inc. stock maintain momentum in 2025 - nchmf.gov.vn
Weekly Earnings: Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Retail Activity & Low Drawdown Trading Strategies - nchmf.gov.vn
What catalysts could drive Taysha Gene Therapies Inc. stock higherJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - nchmf.gov.vn
Taysha Gene Therapies Inc Stock Analysis and ForecastInstitutional Holding Changes & Affordable Portfolio Growth - earlytimes.in
Can Taysha Gene Therapies Inc. stock hit record highs againJuly 2025 Final Week & Growth Focused Stock Pick Reports - nchmf.gov.vn
How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment Story - Yahoo Finance
Sell Signal: Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - nchmf.gov.vn
Taysha regains full rights to Rett syndrome gene therapy program By Investing.com - Investing.com Australia
Why Is Taysha Gene Therapies Stock Falling Friday? - Sahm
Taysha Gene Therapies regains full rights to TSHA-102 - MSN
Earnings visualization tools for Taysha Gene Therapies Inc.Insider Buying & AI Enhanced Trade Execution Alerts - newser.com
Bring it back home: Taysha regains gene therapy as option expires - BioWorld MedTech
I-Mab morphs into ‘hub-and-spoke’ biotech; Astellas passes on Taysha gene therapy - BioPharma Dive
Taysha Gene Therapies regains full rights to TSHA-102 (TSHA:NASDAQ) - Seeking Alpha
Taysha Gene Therapies (TSHA) Rating and Price Target Reaffirmed by Chardan Capital | TSHA Stock News - GuruFocus
Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034 - GlobeNewswire Inc.
Cantor Fitzgerald reiterates Overweight rating on Taysha Gene Therapies stock - Investing.com Canada
Needham Reiterates Taysha Gene Therapies (TSHA) with "Buy" Ratin - GuruFocus
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: 87% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews
Taysha Gene Therapies price target raised to $9 from $8 at BofA - MSN
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright - MSN
Taysha (TSHA) Reclaims Full Rights to Key Rett Syndrome Program - GuruFocus
Taysha Gene Therapies Regains Full Rights to TSHA-102 Program - TradingView
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 - GlobeNewswire
Taysha Regains Full Rights to TSHA-102; 100% Part A Response | TSHA Stock News - Stock Titan
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Taysha Gene Therapies Inc-Aktie (TSHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Option Exercise |
0.70 |
41,150 |
28,760 |
1,206,439 |
| Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Sale |
3.23 |
200,000 |
646,000 |
1,006,439 |
0.03%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):